You are here

Press Releases

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy.

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation Impella CP heart pump at the Annual meeting of the Society for Cardiovascular and Angiography Interventions (SCAI 2017) in New Orleans, LA.

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today that it will be participating in the SCAI 2017 Scientific Sessions to be held May 10-13 in New Orleans, LA.

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door to Unloading (DTU) with Impella CP® system in acute myocardial infarction.

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2017 revenue of $124.7 million, an increase of 33% compared to revenue of $94.0 million for the same period of fiscal 2016. 

Many of the world’s leading interventional cardiologists and cardiovascular professionals will gather in New Orleans May 10-13 for the 40th Annual Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. The meeting coincides with the 40thanniversary of the first coronary angioplasty, a procedure that revolutionized medicine.

MARLBOROUGH, Mass.April 18, 2017 /PRNewswire/ -- Boston Scientific (NYSE:  BSX) has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System who are aged 65 and older with a history of prior heart attack, diabetes and moderately reduced left ventricular ejection fraction.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.

LONDONMarch 30, 2017 /PRNewswire/ -- Trends, opportunities and forecast in this market to 2022 by procedure, which includes repair (annuloplasty, valvuloplasty, transcatheter mitral valve repair, and other repairs) and replacement (surgical valves, mechanical heart valves, tissue heart valves, and transcatheter aortic valves), position (aorta, mitral, and other), and region (North AmericaEuropeAsia Pacific, and the Rest of the World).

Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy for treating patients with persistent atrial fibrillation (AF), using the Arctic Front Advance(TM) Cardiac CryoAblation Catheter. John Harding, M.D., Doylestown Hospital in Doylestown, Penn., treated the first patient enrolled in the trial.

 Enterprise Imaging for Cardiology is a unified, care-centered and sophisticated imaging platform for cardiovascular professionals.

One heartbeat scans with the industry’s fastest rotation speed in a system that is affordable and accessible in the hospital, chest pain emergency (ED), or point-of-care setting.

SDSU researcher uncovers molecular pathway that protects the heart from damage during a heart attack.

Minneapolis Heart Institute Foundation® study finds that presence of cardiac arrest and/or cardiogenic shock is  responsible for more than 75% of hospital deaths in  STEMI patients.
 

The Cities and Communities with Heart Initiative Nashville brings the community together to stop the #1 killer of women
 

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results from the BIOHELIX-I clinical study. This stent, which has already been used to treat more than 650,000 patients worldwide, is now available in the US.

Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and Children’s Hospital of Philadelphia are collaborating to delay and prevent heart failure for hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of a child's heart is severely underdeveloped.

Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.

Pages